Samuel Ap Short1, Katherine Wilkinson2, D Leann Long3, Suzanne Judd3, Janin Schulte4, Brett M Kissela5, George Howard3, Mary Cushman6. 1. Larner College of Medicine, University of Vermont, Burlington, VT. 2. Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT. 3. Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL. 4. SphingoTec GmbH, Hennigsdorf, Germany. 5. Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH. 6. Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT; Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, VT. Electronic address: Mary.Cushman@uvm.edu.
Abstract
OBJECTIVES: The opioid neuropeptide pro-enkephalin A (PENK-A) may be a circulating marker of cardiovascular risk, with prior findings relevant to heart failure, kidney disease, and vascular dementia. Despite these findings, the association of PENK-A with ischemic stroke is unknown, so we examined this association in a prospective cohort study and analyzed differences by race and sex. MATERIALS AND METHODS: The REasons for Geographic and Racial Differences in Stroke study (REGARDS) is a prospective cohort study of 30,239 Black and White adults. Plasma PENK-A was measured in 473 participants that developed first-time ischemic stroke over 5.9 years and 899 randomly selected participants. Cox models adjusted for demographics and stroke risk factors were used to calculate hazard ratios (HRs) of stroke by baseline PENK-A. RESULTS: PENK-A was higher with increasing age, female sex, White race, lower body mass index, and antihypertensive medication use. Each SD higher increment of PENK-A was associated with an adjusted HR of 1.20 (95% CI 1.01-1.42) for stroke, with minimal confounding by stroke risk factors. Spline plots suggested a U-shaped relationship, particularly in White men, with an adjusted HR 3.88 (95% CI 1.94-7.77) for the 95th versus 50th percentile of PENK-A in White men. CONCLUSIONS: Higher baseline plasma PENK-A was independently associated with future stroke risk in REGARDS. This association was most apparent among White men. There was little confounding by established stroke risk factors, suggesting a possible causal role in stroke etiology. Further research is needed to understand the role of endogenous opioids in stroke pathogenesis.
OBJECTIVES: The opioid neuropeptide pro-enkephalin A (PENK-A) may be a circulating marker of cardiovascular risk, with prior findings relevant to heart failure, kidney disease, and vascular dementia. Despite these findings, the association of PENK-A with ischemic stroke is unknown, so we examined this association in a prospective cohort study and analyzed differences by race and sex. MATERIALS AND METHODS: The REasons for Geographic and Racial Differences in Stroke study (REGARDS) is a prospective cohort study of 30,239 Black and White adults. Plasma PENK-A was measured in 473 participants that developed first-time ischemic stroke over 5.9 years and 899 randomly selected participants. Cox models adjusted for demographics and stroke risk factors were used to calculate hazard ratios (HRs) of stroke by baseline PENK-A. RESULTS: PENK-A was higher with increasing age, female sex, White race, lower body mass index, and antihypertensive medication use. Each SD higher increment of PENK-A was associated with an adjusted HR of 1.20 (95% CI 1.01-1.42) for stroke, with minimal confounding by stroke risk factors. Spline plots suggested a U-shaped relationship, particularly in White men, with an adjusted HR 3.88 (95% CI 1.94-7.77) for the 95th versus 50th percentile of PENK-A in White men. CONCLUSIONS: Higher baseline plasma PENK-A was independently associated with future stroke risk in REGARDS. This association was most apparent among White men. There was little confounding by established stroke risk factors, suggesting a possible causal role in stroke etiology. Further research is needed to understand the role of endogenous opioids in stroke pathogenesis.
Authors: Olivier W V van den Brink; Lea M Delbridge; Franklin L Rosenfeldt; Daniel Penny; Donald S Esmore; Deahne Quick; David M Kaye; Salvatore Pepe Journal: Heart Lung Circ Date: 2003 Impact factor: 2.975
Authors: Wolfram Doehner; Stephan von Haehling; Jennifer Suhr; Nicole Ebner; Andreas Schuster; Eike Nagel; Arthur Melms; Thomas Wurster; Konstantinos Stellos; Meinrad Gawaz; Boris Bigalke Journal: J Am Coll Cardiol Date: 2012-07-24 Impact factor: 24.094
Authors: Orlando M Gutiérrez; Suzanne E Judd; Paul Muntner; Dana V Rizk; William M McClellan; Monika M Safford; Mary Cushman; Brett M Kissela; Virginia J Howard; David G Warnock Journal: Neurology Date: 2012-09-19 Impact factor: 9.910
Authors: Howard D Sesso; Julie E Buring; William G Christen; Tobias Kurth; Charlene Belanger; Jean MacFadyen; Vadim Bubes; JoAnn E Manson; Robert J Glynn; J Michael Gaziano Journal: JAMA Date: 2008-11-09 Impact factor: 56.272
Authors: Debora Kamin Mukaz; Neil A Zakai; Salvador Cruz-Flores; Louise D McCullough; Mary Cushman Journal: Stroke Date: 2020-10-26 Impact factor: 7.914